Workflow
和仁科技(300550) - 2021 Q3 - 季度财报
Heren HealthHeren Health(SZ:300550)2021-10-28 16:00

Financial Performance - The company's revenue for Q3 2021 was ¥114,151,786.04, a decrease of 8.70% compared to the same period last year[2] - Net profit attributable to shareholders was ¥16,103,037.67, down 10.84% year-on-year, while net profit excluding non-recurring gains and losses was ¥14,353,317.61, a decrease of 7.89%[2] - Year-to-date net profit attributable to shareholders increased by 42.29% to ¥35,259,577.02, driven by increased sales collections[8] - Total operating revenue for Q3 2021 was CNY 305,919,027.71, an increase of 5.5% compared to CNY 289,953,055.30 in Q3 2020[21] - Net profit for Q3 2021 reached CNY 34,997,375.62, representing a significant increase of 50.5% compared to CNY 23,267,690.74 in Q3 2020[22] - The total comprehensive income for the period was CNY 35,259,577.02, compared to CNY 24,780,665.09 in the previous period, representing an increase of approximately 42.3%[23] - Basic and diluted earnings per share increased to CNY 0.13 from CNY 0.11, reflecting a growth of 18.2%[23] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was -¥64,613,164.63, reflecting a 48.38% increase compared to the same period last year[2] - Cash inflow from operating activities totaled CNY 296,476,836.91, up from CNY 193,298,757.19, marking a rise of 53.5%[26] - The net cash flow from operating activities was -CNY 64,613,164.63, an improvement from -CNY 125,171,918.51 in the previous period[26] - Cash inflow from investment activities was CNY 1,124,836,930.68, significantly higher than CNY 290,872,925.03, indicating an increase of 286.5%[26] - The net cash flow from investment activities was CNY 31,502,123.13, down from CNY 110,600,811.56, a decrease of 71.5%[26] - Cash inflow from financing activities was CNY 110,000,000.00, compared to CNY 629,617,592.57 in the previous period, a decline of 82.5%[27] - The net cash flow from financing activities was -CNY 96,387,211.95, contrasting with a positive CNY 534,346,284.15 in the previous period[27] - The ending cash and cash equivalents balance was CNY 301,948,782.46, down from CNY 737,493,430.76, a decrease of 59.0%[27] - Total assets at the end of the reporting period were ¥1,447,876,908.09, a decrease of 7.33% from the end of the previous year[3] - The company's total assets decreased to CNY 1,447,876,908.09 as of September 30, 2021, down from CNY 1,562,326,060.38 at the end of 2020[19] Shareholder and Equity Information - The weighted average return on equity was 1.42%, down 1.35% year-on-year[3] - The company reported a basic earnings per share of ¥0.06, a decrease of 25.00% compared to the same period last year[2] - The company has not undergone any changes in share capital due to new share issuance or other reasons during the reporting period[3] - The top ten shareholders include Hangzhou Panyuan Investment Co., Ltd. with a 44.28% stake, which is pledged[10] - The company's equity attributable to shareholders increased to CNY 1,140,828,249.02, up from CNY 1,095,082,733.06, reflecting a growth of 4.2%[19] Restricted Shares and Incentive Plans - The total number of restricted shares at the end of the period is 3,703,688 shares, with no shares released during the current period[15] - The company has a stock incentive plan where restricted shares are released in four tranches of 25% each, based on audited performance and individual assessments[14] - The stock incentive plan includes key executives with varying numbers of restricted shares, such as Ren Hongming with 1,213,737 shares and Yao Jianmin with 411,600 shares[13] - The company disclosed that the restricted shares are subject to a lock-up period of 12 to 48 months, depending on the specific terms of the incentive plan[14] - The total number of restricted shares for Zhang Xuefeng is 378,478, while for Zhu Hui it is 219,520 shares[14] - The company emphasizes the importance of performance evaluations in the unlocking of restricted shares, which are tied to the company's audited financial results[15] - The stock incentive plan is designed to align the interests of executives with the company's performance and shareholder value[14] - The company has not released any new restricted shares during the current reporting period[15] - The stock incentive plan is publicly available on the company's disclosure platform, ensuring transparency[14] - The total number of restricted shares held by executives reflects the company's commitment to incentivizing key personnel[13] Operating Costs and Expenses - Total operating costs for Q3 2021 were CNY 271,906,149.37, up from CNY 257,217,055.68 in the same period last year, reflecting a year-on-year increase of 5.7%[21] - Research and development expenses increased to CNY 35,048,778.93 in Q3 2021, compared to CNY 29,765,984.75 in Q3 2020, marking a rise of 17.5%[22] - Current liabilities decreased to CNY 274,990,391.85 from CNY 434,922,858.69, indicating a reduction of 36.7%[18] - The company reported a significant decrease in short-term borrowings, which fell to CNY 50,104,222.22 from CNY 130,109,694.44, a reduction of 61.4%[18] - Cash and cash equivalents decreased to CNY 307,071,272.35 from CNY 440,209,354.52, a decline of 30.2%[17] - Inventory increased to CNY 71,022,885.96, compared to CNY 50,006,256.76 in the previous year, representing a growth of 42.0%[17] Accounting Standards - The company did not require adjustments to the beginning balance sheet items under the new leasing standards implemented from January 1, 2021[28]